文献速递白血病

Eprenetapopt联合维奈克拉和阿扎胞苷治疗TP53突变急性髓系白血病:1期剂量探索与扩展研究

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
PubMed 文献 · Lancet Haematol · 2023-01-01

这项在美国8家学术研究医院开展的1期多中心开放标签剂量探索与队列扩展研究,纳入49例初治TP53突变急性髓系白血病患者,评估Eprenetapopt联合维奈克拉(队列1)及再加阿扎胞苷(队列2及扩展)的安全性与疗效。未观察到剂量限制性毒性,Eprenetapopt推荐2期剂量为4.5 g/天第1-4天;扩展队列39例中25例(64%,95%CI 47-79)总体缓解,15例(38%,95%CI 23-55)完全缓解。

要点

  • Eprenetapopt联合维奈克拉及阿扎胞苷未观察到剂量限制性毒性,推荐2期剂量为Eprenetapopt 4.5 g/天第1-4天。
  • 49例中3级及以上不良事件≥20%者包括发热性中性粒细胞减少23例(47%)、血小板减少18例(37%)、白细胞减少12例(25%)、贫血11例(22%)。
  • 扩展队列39例中总体缓解25例(64%,95%CI 47-79),完全缓解15例(38%,95%CI 23-55)。

核心结论

  • Eprenetapopt联合维奈克拉及阿扎胞苷安全性可接受且活性令人鼓舞,支持进一步一线评估该联合方案治疗TP53突变急性髓系白血病。

研究设计与样本

  • 1期多中心开放标签剂量探索与队列扩展研究,在美国8家学术研究医院开展,纳入年龄≥18岁、至少一种致病性TP53突变、按2016年WHO分类初治急性髓系白血病、ECOG体能状态0-2、预期寿命至少12周的患者。
  • 剂量探索队列1允许既往因骨髓增生异常综合征接受去甲基化药物治疗,队列2不允许既往使用去甲基化药物;治疗周期28天。
  • 队列1接受静脉Eprenetapopt 4.5 g/天第1-4天联合口服维奈克拉400 mg/天第1-28天;队列2另接受皮下或静脉阿扎胞苷75 mg/m2第1-7天;扩展部分按队列2入组。
  • 主要终点为所有队列的安全性(评估至少接受一剂分配治疗的患者)和扩展队列的完全缓解(评估完成至少一个治疗周期且至少一次治疗后临床缓解评估的患者)。
  • 2020年1月3日至2021年7月22日共入组49例;剂量探索队列1和2各初始入组6例,未观察到剂量限制性毒性后队列2扩展额外入组37例。

主要发现

  • 中位年龄67岁(IQR 59-73);49例中女性24例(49%)、男性25例(51%),40例(82%)为白人。
  • 数据截止2021年10月1日,中位随访9.5个月(IQR 6.1-11.5);未记录到剂量限制性毒性,Eprenetapopt联合方案的推荐2期剂量为4.5 g/天第1-4天。
  • 所有患者中发生率至少20%的3级及以上不良事件为发热性中性粒细胞减少23例(47/49)、血小板减少18例(37%)、白细胞减少12例(25%)、贫血11例(22%)。
  • 治疗相关严重不良事件发生于13例(27/49),治疗相关死亡1例(2%,脓毒症)。
  • 39例接受Eprenetapopt联合维奈克拉及阿扎胞苷的患者中,总体缓解25例(64%,95%CI 47-79),完全缓解15例(38%,95%CI 23-55)。

关键数值与推荐

  • Eprenetapopt联合方案的推荐2期剂量为4.5 g/天第1-4天。
  • 扩展队列39例中总体缓解25例(64%,95%CI 47-79),完全缓解15例(38%,95%CI 23-55)。
  • 3级及以上不良事件中发热性中性粒细胞减少23例(47/49)、血小板减少18例(37/49)、白细胞减少12例(25/49)、贫血11例(22/49)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TP53-mutated acute myeloid leukaemia is associated with poor outcomes. Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. We aimed to evaluate the combination of eprenetapopt and venetoclax with or without azacitidine in patients with TP53-mutated acute myeloid leukaemia. METHODS: This phase 1, multicentre, open-label, dose-finding and cohort expansion study was done at eight academic research hospitals in the USA. Inclusion criteria were age of at least 18 years; at least one pathogenic TP53 mutation; treatment-naive acute myeloid leukaemia according to the 2016 WHO classification; an ECOG performance status of 0-2; and a life expectancy of at least 12 weeks. In dose-finding cohort 1 patients received previous therapy with hypomethylating agents for myelodysplastic syndromes. In dose-finding cohort 2, previous use of hypomethylating agents was not permitted. Treatment cycles were 28 days. Patients in cohort 1 received intravenous eprenetapopt 4·5 g/day on days 1-4 and oral venetoclax 400 mg/day on days 1-28; those in cohort 2 also received subcutaneous or intravenous azacitidine 75 mg/m2 on days 1-7. The expansion part of the study proceeded with patients enrolled as in cohort 2. Primary endpoints were safety in all cohorts (assessed in patients receiving at least one dose of assigned treatment) and complete response in the expansion cohort (assessed in patients who completed at least one treatment cycle and had at least one post-treatment clinical response assessment). The trial is registered with ClinicalTrials.gov, NCT04214860, and is complete. FINDINGS: Between Jan 3, 2020, and July 22, 2021, 49 patients were enrolled across all cohorts. Six patients were initially enrolled into each of dose-finding cohorts 1 and 2; after no dose-limiting toxicities were observed, cohort 2 was expanded to enrol an additional 37 patients. The median age was 67 years (IQR 59-73). 24 (49%) of 49 patients were female and 25 (51%) male, and 40 (82%) were White. At data cutoff (Oct 1, 2021), the median length of follow-up was 9·5 months (IQR 6·1-11·5). No dose-limiting toxicities were recorded and the recommended phase 2 dose for eprenetapopt combinations was 4·5 g/day on days 1-4. Across all patients, adverse events of grade 3 or worse occurring in at least 20% of patients were febrile neutropenia (23 [47%] of 49 patients), thrombocytopenia (18 [37%] patients), leukopenia (12 [25%] patients), and anaemia (11 [22%] patients). Treatment-related serious adverse events occurred in 13 (27%) of 49 patients and there was one (2%) treatment-related death (sepsis). 25 (64%, 95% CI 47-79) of 39 patients had an overall response with eprenetapopt and venetoclax with azacytidine; 15 (38%, 23-55) had a complete response. INTERPRETATION: Eprenetapopt and venetoclax with azacitidine had an acceptable safety profile and encouraging activity, supporting further frontline evaluation of this combination in the treatment of TP53-mutated acute myeloid leukaemia. FUNDING: Aprea Therapeutics.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Garcia-Manero G, Goldberg AD, Winer ES, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023. PMID: 36990622. doi:10.1016/S2352-3026(22)00403-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。